Uroplasty Previews Urgent® PC Presentations at the American Urological Association 2012 Annual Meeting
MINNEAPOLIS, May 17, 2012 /PRNewswire/ — Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that at the May 19-22, 2012 Annual Meeting of the American Urological Association (AUA) in Atlanta, GA, there will be two presentations on Uroplasty’s Urgent® PC Neuromodulation System.
“The presentations on Urgent PC scheduled for the AUA meeting will feature the results of two important follow-up studies by leading urologists. This data will be presented to urologists from around the world at the 2012 AUA Annual Meeting,” said David Kaysen, President and CEO of Uroplasty.
Urgent PC presentations
- “30 Month Study Results Using Percutaneous Tibial Nerve Stimulation: Long Term Efficacy Outcomes” presented by Kenneth M. Peters, MD, Beaumont Hospital, Royal Oak, MI.
- “Neurostimulation Treatment For Overactive Bladder: An Evaluation of Cost Effectiveness Data” presented by Scott MacDiarmid, MD, Alliance Urology Specialists, Greensboro, NC.
“Dr. Ken Peters will present 30-month data from the STEP study, which shows sustained long term clinically significant benefits for patients with overactive bladder (OAB) who responded to the initial 12-week Urgent PC therapy in the SUmiT study. The findings show sustained improvements for frequency, incontinence episodes, nighttime voids, moderate to severe urgency and quality of life measures. The findings Dr. Peters will present are in addition to the 24-month STEP study findings accepted by and expected to be published in Neurourology and Urodynamics.
“Dr. Scott MacDiarmid will present the clinical and cost effectiveness of the office-based Urgent PC Neuromodulation System compared to surgically-implanted sacral nerve stimulation. The results of this study indicate both Urgent PC and sacral nerve stimulation are effective neuromodulation therapies for the treatment of OAB, with Urgent PC offering equivalent results at a substantially lower cost,” Mr. Kaysen continued.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent(®) PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers percutaneous tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique(®) Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Uroplasty, Inc. EVC Group --------------- --------- David Kaysen, President and CEO, or Jenifer Kirtland (Investors) Medi Jiwani, Vice President, CFO, and Treasurer, 415.568.9349 952.426.6140 Chris Gale (Media) 646.201.5431
SOURCE Uroplasty, Inc.